Opendata, web and dolomites

RSVTriVax SIGNED

Development of a trivalent epitope-focused RSV vaccine to boost pre-existing immunity

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RSVTriVax project word cloud

Explore the words cloud of the RSVTriVax project. It provides you a very rough idea of what is the project "RSVTriVax" about.

competitive    rsv    epitope    molecular    eliciting    profile    immunogens    trivax    young    syncytial    good    neutralizing    global    compelling    infection    elderly    societal    animal    world    elicited    viral    120    carries    populations    episodes    approved    emerge    clinically    superior    cocktail    stable    sophisticated    human    functional    manufacturing    annually    competitor    globally    infections    abs    protect    million    pregnant    scenario    organization    deemed    pathogen    iuml    burdens    subdominant    na    protection    ve    strongest    thereby    boosting    formulation    preliminary    financial    model    immune    showed    attributed    tools    women    virus    33    exquisite    promise    primary    intensive    commercial    boost    molecules    mechanisms    consolidate    candidate    cohort    protective    health    alternative    public    natural    mostly    prevent    edge    decades    children    mimicking    infants    neutralization    causes    induction    potent    candidates    suggesting    epitopes    vaccine    yield    cutting    deaths    antibodies    respiratory    close    primates    safety   

Project "RSVTriVax" data sheet

The following table provides information about the project.

Coordinator
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE 

Organization address
address: BATIMENT CE 3316 STATION 1
city: LAUSANNE
postcode: 1015
website: www.epfl.ch

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE CH (LAUSANNE) coordinator 150˙000.00

Map

 Project objective

The development of a Respiratory Syncytial Virus (RSV) vaccine is deemed a global health priority by the World Health Organization. Globally, RSV causes 33 million episodes of infection and up to 120,000 deaths annually. The most affected populations are pre-term infants, young children and the elderly. Several decades of intensive research are yet to yield a clinically approved vaccine. This failure is mostly attributed to sophisticated viral mechanisms that prevent the induction of protective antibodies (Abs). Using cutting-edge molecular design tools, we developed a novel vaccine candidate (TriVax) to focus immune responses in such key neutralization epitopes. TriVax is a cocktail composed of three epitope-focused immunogens mimicking three distinct neutralization epitopes targeted by potent neutralizing Abs. Our primary target populations are pregnant women (protection of pre-term infants) and elderly, where the challenge is to boost subdominant, neutralizing Abs elicited during previous natural infections. Recently, we showed that epitope-focused immunogens are exquisite at boosting subdominant functional Abs, and in this scenario, superior to the strongest competitor vaccine candidates. In a preliminary study in Non-Human Primates, TriVax showed great promise by eliciting robust neutralization on an RSV naïve cohort, suggesting a good safety profile and the potential to emerge as a competitive alternative for vaccine development. For manufacturing, epitope-focused immunogens are simple and stable molecules that can be produced at low cost. Overall, we propose a viable vaccine formulation to protect against an important pathogen which carries large financial burdens on public health systems. Thus, our proposal has an important societal and financial impact, and will provide compelling evidence for Trivax to boost neutralizing Abs in a close-to-human animal model, thereby taking an essential step to consolidate the commercial potential of our vaccine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RSVTRIVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RSVTRIVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

ENUF (2019)

Evaluation of Novel Ultra-Fast selective III-V Epitaxy

Read More  

PEGASOS (2019)

Photon Emitting Gated Arrays for Scalable On-chip quantum Systems

Read More  

POLIVERNACULARS (2020)

India's Politics in Its Vernaculars

Read More